Anti-C3 antibody [11H9] (ab11862)

Rat monoclonal C3 antibody [11H9]. Validated in WB, IP, ELISA, IHC, Flow Cyt, ICC/IF and tested in Mouse. Cited in 20 publication(s). Independently reviewed in 2 review(s).


  • Product name

    Anti-C3 antibody [11H9]
    See all C3 primary antibodies
  • Description

    Rat monoclonal [11H9] to C3
  • Host species

  • Specificity

    This antibody recognizes both intact C3 and its cleaved products C3b, iC3b, C3d and C3dg. The mature protein C3 has a molecular weight of approximately 190 kDa. The complement factor C3 consists of an alpha- and a beta-chain, linked by disulfide bond. C3 convertase activates C3 by cleaving the alpha chain, releasing C3a anaphylotoxin and generating C3b (alpha chain and beta chain). C3b has a molecular weight of approximately 185 kDa. C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. iC3b has a molecular weight of approximately 182 kDa. Does not cross react with C4.
  • Tested applications

    Suitable for: ELISA, ICC/IF, WB, Flow Cyt, IHC-Fr, IPmore details
  • Species reactivity

    Reacts with: Mouse
    Does not react with: Human
  • Immunogen

    C57BL/6 thymocytes saturated with rat anti-Thy-1 monoclonal antibody of IgG2b subclass (RmT1).

  • General notes

    In response to recent customer complaints for IHC-P with paraffin embedded sections we no longer guarantee this application.



Our Abpromise guarantee covers the use of ab11862 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use a concentration of 0.5 µg/ml.

Use as coating antibody at 0.5 ug/well in PBS.

ICC/IF Use at an assay dependent concentration.
WB 1/50. Predicted molecular weight: 187 kDa.
Flow Cyt 1/50.

ab18450 - Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody.

IHC-Fr 1/50.

Fix tissue sections in acetone.

IP 1/50.


  • Function

    C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
    Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
  • Tissue specificity

  • Involvement in disease

    Defects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:120700]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
    Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
    Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
  • Sequence similarities

    Contains 1 anaphylatoxin-like domain.
    Contains 1 NTR domain.
  • Post-translational

    C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g.
    Phosphorylation sites are present in the extracelllular medium.
  • Cellular localization

  • Information by UniProt
  • Database links

  • Alternative names

    • Acylation stimulating protein cleavage product antibody
    • AHUS5 antibody
    • ARMD9 antibody
    • ASP antibody
    • C3 and PZP like alpha 2 macroglobulin domain containing protein 1 antibody
    • C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 antibody
    • C3 antibody
    • c3 complement antibody
    • C3adesArg antibody
    • CO3_HUMAN antibody
    • Complement C3 alpha chain antibody
    • Complement C3 antibody
    • Complement C3b alpha' chain antibody
    • Complement C3c alpha' chain fragment 1 antibody
    • Complement C3c alpha' chain fragment 2 antibody
    • Complement C3c alpha'' chain fragment 2 antibody
    • Complement C3d fragment antibody
    • Complement C3dg fragment antibody
    • Complement C3f fragment antibody
    • Complement C3g fragment antibody
    • Complement component 3 antibody
    • Complement factor 3 antibody
    • CPAMD1 antibody
    • HEL S 62p antibody
    • omplement C3 beta chain antibody
    see all


  • Immunohistochemical analysis of mouse sciatic nerve section, labelling C3 with ab11862. Mice were intracardially perfused with 4% paraformaldehyde/PBS solution. Following dissection, the sciatic nerve section was embedded and cro-sectioned and immunostained with ab11862 at 1/100. 

  • ab11862 staining C3 in murine kidney cells by Immunocytochemistry/ Immunofluorescence.
    C3 protein fragments deposited on kidney cells of MPL-lpr mouse. Glomerular staining pattern.


This product has been referenced in:

  • Ugarte-Berzal E  et al. MMP-9/Gelatinase B Degrades Immune Complexes in Systemic Lupus Erythematosus. Front Immunol 10:538 (2019). Read more (PubMed: 30967870) »
  • Illouz T  et al. Restoring microglial and astroglial homeostasis using DNA immunization in a Down Syndrome mouse model. Brain Behav Immun 75:163-180 (2019). Read more (PubMed: 30389461) »
See all 23 Publications for this product

Customer reviews and Q&As

Filter by Application

Filter by Species

Filter by Ratings

1-3 of 3 Abreviews

Immunohistochemistry (PFA perfusion fixed frozen sections)
Mouse Tissue sections (Adult brain)
Antigen retrieval step
Yes - Triton 0.3%
Adult brain
Blocking step
BSA as blocking agent for 1 hour(s) and 30 minute(s) · Concentration: 3% · Temperature: 21°C

Dr. Sébastien Brot

Verified customer

Submitted Jul 09 2019

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Mouse Tissue sections (ischemia/reperfusion injury)
Antigen retrieval step
Heat mediated - Buffer/Enzyme Used: citrate pH6.0
ischemia/reperfusion injury
Blocking step
BSA as blocking agent for 30 minute(s) · Concentration: 5% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Mar 14 2016

Western blot
Mouse Serum (Mouse Serum)
Gel Running Conditions
Reduced Denaturing (12%)
Loading amount
10 µg
Mouse Serum
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C

Haoran Zha

Verified customer

Submitted Jan 21 2016

For licensing inquiries, please contact

Sign up